Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of October 26th – November 1st, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
Following RWB’s IPO This Summer, the Company Has Executed Flawlessly Closing a Legendary String of Deals Including the Blockbuster High Times and Platinum Vape Deals
Rising cannabis Multi-State Operator (MSO) and new kid on the block Red White & Bloom (OTCQX: RWBYF) has quickly made a name for itself in a very competitive American Marijuana industry alongside big names like Trulieve (OTCQX: TCNNF), Curaleaf (OTCQX: CURLF), Green Thumb (OTCQX: GTBIF) and Cresco Labs (OTCQX: CRLBF).
The Recent Publication of the Potential of N-acetyl-cysteine (NAC) in the Treatment of COVID-191 Serves as Further Validation for Bucillamine
Revive Therapeutics (OTCPK: RVVTF) announced an update on the company’s U.S. FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020.
The Research Will Be Led By Prof. Dr. Gerhard Gründer, the Only confirmed Scientist Developing a Study to Work With Psychedelics in Germany Since the 1970s
Havn Life Sciences (CSE: HAVN) announced the company has signed on to support ground-breaking research with the MIND Foundation on a study on